S&P 500   3,692.28 (+0.70%)
DOW   30,141.31 (+0.57%)
QQQ   305.46 (+0.39%)
AAPL   122.06 (-0.72%)
MSFT   214.04 (-0.09%)
FB   280.58 (-0.45%)
GOOGL   1,824.40 (+0.14%)
AMZN   3,176.77 (-0.31%)
TSLA   594.54 (+0.20%)
NVDA   540.79 (+0.92%)
BABA   267.37 (+0.17%)
CGC   29.09 (+1.61%)
GE   10.74 (+1.32%)
MU   73.75 (+5.51%)
AMD   93.94 (+1.77%)
T   29.55 (+1.09%)
NIO   43.09 (-4.98%)
F   9.38 (+1.85%)
ACB   11.85 (+5.43%)
BA   230.66 (-2.76%)
NFLX   499.69 (+0.44%)
GILD   61.32 (+0.76%)
DIS   153.79 (+0.36%)
S&P 500   3,692.28 (+0.70%)
DOW   30,141.31 (+0.57%)
QQQ   305.46 (+0.39%)
AAPL   122.06 (-0.72%)
MSFT   214.04 (-0.09%)
FB   280.58 (-0.45%)
GOOGL   1,824.40 (+0.14%)
AMZN   3,176.77 (-0.31%)
TSLA   594.54 (+0.20%)
NVDA   540.79 (+0.92%)
BABA   267.37 (+0.17%)
CGC   29.09 (+1.61%)
GE   10.74 (+1.32%)
MU   73.75 (+5.51%)
AMD   93.94 (+1.77%)
T   29.55 (+1.09%)
NIO   43.09 (-4.98%)
F   9.38 (+1.85%)
ACB   11.85 (+5.43%)
BA   230.66 (-2.76%)
NFLX   499.69 (+0.44%)
GILD   61.32 (+0.76%)
DIS   153.79 (+0.36%)
S&P 500   3,692.28 (+0.70%)
DOW   30,141.31 (+0.57%)
QQQ   305.46 (+0.39%)
AAPL   122.06 (-0.72%)
MSFT   214.04 (-0.09%)
FB   280.58 (-0.45%)
GOOGL   1,824.40 (+0.14%)
AMZN   3,176.77 (-0.31%)
TSLA   594.54 (+0.20%)
NVDA   540.79 (+0.92%)
BABA   267.37 (+0.17%)
CGC   29.09 (+1.61%)
GE   10.74 (+1.32%)
MU   73.75 (+5.51%)
AMD   93.94 (+1.77%)
T   29.55 (+1.09%)
NIO   43.09 (-4.98%)
F   9.38 (+1.85%)
ACB   11.85 (+5.43%)
BA   230.66 (-2.76%)
NFLX   499.69 (+0.44%)
GILD   61.32 (+0.76%)
DIS   153.79 (+0.36%)
S&P 500   3,692.28 (+0.70%)
DOW   30,141.31 (+0.57%)
QQQ   305.46 (+0.39%)
AAPL   122.06 (-0.72%)
MSFT   214.04 (-0.09%)
FB   280.58 (-0.45%)
GOOGL   1,824.40 (+0.14%)
AMZN   3,176.77 (-0.31%)
TSLA   594.54 (+0.20%)
NVDA   540.79 (+0.92%)
BABA   267.37 (+0.17%)
CGC   29.09 (+1.61%)
GE   10.74 (+1.32%)
MU   73.75 (+5.51%)
AMD   93.94 (+1.77%)
T   29.55 (+1.09%)
NIO   43.09 (-4.98%)
F   9.38 (+1.85%)
ACB   11.85 (+5.43%)
BA   230.66 (-2.76%)
NFLX   499.69 (+0.44%)
GILD   61.32 (+0.76%)
DIS   153.79 (+0.36%)
Log in
NASDAQ:AMGN

Amgen Stock Forecast, Price & News

Most-Downgraded Stocks  
$228.90
+1.99 (+0.88 %)
(As of 12/4/2020 12:46 PM ET)
Add
Compare
Today's Range
$225.79
Now: $228.90▼
$229.13
50-Day Range
$216.38
MA: $228.00▼
$241.60
52-Week Range
$177.05
Now: $228.90▼
$264.97
Volume38,419 shs
Average Volume2.84 million shs
Market Capitalization$133.26 billion
P/E Ratio18.46
Dividend Yield2.82%
Beta0.76
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Amgen logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

2.46 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
Previous Symbol
CUSIP03116210
CIK318154
Webwww.amgen.com
Phone805-447-1000
Employees23,400

Debt

Debt-to-Equity Ratio3.12
Current Ratio2.28
Quick Ratio1.88

Price-To-Earnings

Trailing P/E Ratio18.46
Forward P/E Ratio14.17
P/E Growth1.9

Sales & Book Value

Annual Sales$23.36 billion
Price / Sales5.70
Cash Flow$19.50 per share
Price / Cash Flow11.74
Book Value$18.82 per share
Price / Book12.16

Profitability

EPS (Most Recent Fiscal Year)$14.82
Net Income$7.84 billion
Net Margins29.42%
Return on Equity95.55%
Return on Assets15.52%

Miscellaneous

Outstanding Shares582,169,000
Market Cap$133.26 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$228.90
+1.99 (+0.88 %)
(As of 12/4/2020 12:46 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amgen (NASDAQ:AMGN) Frequently Asked Questions

How has Amgen's stock been impacted by Coronavirus?

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMGN stock has increased by 15.1% and is now trading at $228.55.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Amgen?

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 12 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amgen or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Amgen?

Wall Street analysts have given Amgen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amgen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Amgen.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) released its earnings results on Monday, November, 2nd. The medical research company reported $4.37 earnings per share for the quarter, beating the consensus estimate of $3.75 by $0.62. The medical research company had revenue of $6.42 billion for the quarter, compared to analysts' expectations of $6.38 billion. Amgen had a net margin of 29.42% and a return on equity of 95.55%.
View Amgen's earnings history.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Wednesday, October 21st. Shareholders of record on Monday, November 16th will be paid a dividend of $1.60 per share on Tuesday, December 8th. This represents a $6.40 dividend on an annualized basis and a yield of 2.80%. The ex-dividend date of this dividend is Friday, November 13th.
View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY20 earnings guidance on Wednesday, October, 28th. The company provided earnings per share (EPS) guidance of $15.80-16.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.78. The company issued revenue guidance of $25.1-25.5 billion, compared to the consensus revenue estimate of $25.39 billion.

What price target have analysts set for AMGN?

28 Wall Street analysts have issued 12-month price targets for Amgen's shares. Their forecasts range from $185.00 to $304.00. On average, they anticipate Amgen's stock price to reach $254.08 in the next twelve months. This suggests a possible upside of 11.2% from the stock's current price.
View analysts' price targets for Amgen.

Who are some of Amgen's key competitors?

Some companies that are related to Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).
View all competitors.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and The Home Depot (HD).

Who are Amgen's key executives?

Amgen's management team includes the following people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 57, Pay $5.61M)
  • Mr. Jonathan P. Graham, Exec. VP, Gen. Counsel & Sec. (Age 59, Pay $2.44M)
  • Dr. David M. Reese M.D., Exec. VP of R&D (Age 57, Pay $2.54M)
  • Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 53, Pay $2.66M)
  • Mr. Peter H. Griffith, Exec. VP & CFO (Age 61)
  • Mr. Esteban Santos, Exec. VP of Operations (Age 52)
  • Ms. Linda H. Louie, VP of Fin. & Chief Accounting Officer
  • Mr. Mike Zahigian, Sr. VP & Chief Information Officer
  • Mr. Arvind Sood, VP of Investor Relations
  • Nancy A. Grygiel, Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.24%), State Street Corp (5.37%), Morgan Stanley (1.47%), Nuveen Asset Management LLC (0.69%), UBS Asset Management Americas Inc. (0.57%) and Charles Schwab Investment Management Inc. (0.47%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar and Tyler Jacks.
View institutional ownership trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Los Angeles Capital Management & Equity Research Inc., Allianz Asset Management GmbH, CIBC Private Wealth Group LLC, O Shaughnessy Asset Management LLC, AQR Capital Management LLC, Coho Partners Ltd., and LSV Asset Management. Company insiders that have sold Amgen company stock in the last year include David Piacquad, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen.

Which institutional investors are buying Amgen stock?

AMGN stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, California Public Employees Retirement System, Morgan Stanley, DekaBank Deutsche Girozentrale, Candriam Luxembourg S.C.A., State of Tennessee Treasury Department, ProShare Advisors LLC, and Capital Wealth Planning LLC.
View insider buying and selling activity for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $228.55.

How big of a company is Amgen?

Amgen has a market capitalization of $133.05 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.